HIV reverse transcriptase(RT)inhibitors are the important components of highly active antiretroviral therapies(HAARTs)for anti-HIV treatment and pre-exposure prophylaxis in clinical practice.Many RT inhibitors and the...HIV reverse transcriptase(RT)inhibitors are the important components of highly active antiretroviral therapies(HAARTs)for anti-HIV treatment and pre-exposure prophylaxis in clinical practice.Many RT inhibitors and their combination regimens have been approved in the past ten years,but a review on their drug discovery,pharmacology,and clinical efficacy is lacking.Here,we provide a comprehensive review of RT inhibitors(tenofovir alafenamide,rilpivirine,doravirine,dapivirine,azvudine and elsulfavirine)approved in the past decade,regarding their drug discovery,pharmacology,and clinical efficacy in randomized controlled trials.Novel RT inhibitors such as islatravir,MK-8504,MK-8507,MK8583,IQP-0528,and MIV-150 will be also highlighted.Future development may focus on the new generation of novel antiretroviral inhibitors with higher bioavailability,longer elimination half-life,more favorable side-effect profiles,fewer drug–drug interactions,and higher activities against circulating drug-resistant strains.展开更多
基金This work was funded by the National Nature Science Foundation of China(31871324,81730064,31571368,China)the Hunan Youth Elite Project(2018RS3006,China)the National Science and Technology Major Project(2018ZX10715004,China).
文摘HIV reverse transcriptase(RT)inhibitors are the important components of highly active antiretroviral therapies(HAARTs)for anti-HIV treatment and pre-exposure prophylaxis in clinical practice.Many RT inhibitors and their combination regimens have been approved in the past ten years,but a review on their drug discovery,pharmacology,and clinical efficacy is lacking.Here,we provide a comprehensive review of RT inhibitors(tenofovir alafenamide,rilpivirine,doravirine,dapivirine,azvudine and elsulfavirine)approved in the past decade,regarding their drug discovery,pharmacology,and clinical efficacy in randomized controlled trials.Novel RT inhibitors such as islatravir,MK-8504,MK-8507,MK8583,IQP-0528,and MIV-150 will be also highlighted.Future development may focus on the new generation of novel antiretroviral inhibitors with higher bioavailability,longer elimination half-life,more favorable side-effect profiles,fewer drug–drug interactions,and higher activities against circulating drug-resistant strains.
